Tag Archive for: Obesity

Antag Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Lead Molecule, AT-7687

/in

Copenhagen, Denmark – October 9, 2024 – Antag Therapeutics, a leading biopharmaceutical company focused on targeting the Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor to pioneer novel treatments for obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for its lead molecule, AT-7687. This milestone enables Antag […]

Read more

QL Biopharm Presented Results from Phase 1c Clinical Study on its Novel Once-Monthly GLP-1RA ZT002 at EASD 2024

/in

– ZT002 was safe and well tolerated in both biweekly and monthly dosing arms in patients with overweight or obesity with a tolerability profile aligned with the GLP-1RA class – The open-label extension with ZT002 120 mg, once-monthly, showed 17.1% reduction in body weight at 30 weeks Beijing, China, 12 September 2024 – Beijing QL […]

Read more

QL Biopharm Announces Abstract on Novel Ultra Long-acting GLP-1RA to be Presented at EASD Annual Meeting 2024

/in

– Abstract on data from a two-part phase 1c, multiple ascending dose study accepted for oral presentation – – New data highlighting the Company’s lead drug candidate ZT002 for obesity – Beijing, China, 3 September 2024 – Beijing QL Biopharmaceutical Co., Ltd. (“QL Biopharm”), a clinical stage biopharmaceutical company developing innovative biologic drugs for the […]

Read more